Alnylam Pharmaceuticals, Inc.
SERPINA1 SIRNAS: COMPOSITIONS OF MATTER AND METHODS OF TREATMENT
Last updated:
Abstract:
The technology described herein relates to double-stranded ribonucleic acid (dsRNA) compositions targeting the Serpina1 gene, and methods of using such dsRNA compositions to inhibit expression of Serpina1.
Status:
Application
Type:
Utility
Filling date:
5 Oct 2021
Issue date:
19 May 2022